絞り込み

16525

広告

「hepatocellular carcinoma or hepatoma or hcc and wilson disease」の検索結果

114275件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Non-alcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Enhanced Nanoparticle Uptake into Virus Infected Cells: Could Nanoparticles be useful in Antiviral Therapy?

In vitro toxicity and in silico docking analysis of two novel selective AH-receptor modulators.

Metastatic hepatocellular carcinoma of small bowel presenting as GI bleeding.

Upregulation of Twist is involved in Gli1 induced migration and invasion of hepatocarcinoma cells.

Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets.

Angio-CT-Guided Transarterial Chemoembolization Immediately in Combination with Radiofrequency Ablation for Large Hepatocellular Carcinoma.

A rare CHD5 haplotype and its interactions with environmental factors predicting hepatocellular carcinoma risk.

Transient receptor potential vanilloid-type 2 targeting on stemness in liver cancer.

Linc-POU3F3 is overexpressed in hepatocellular carcinoma and regulates cell proliferation, migration and invasion.

Real-time imaging tracking of a dual-fluorescent drug delivery system based on doxorubicin-loaded globin- polyethylenimine nanoparticles for visible tumor therapy.

Deferoxamine suppresses esophageal squamous cell carcinoma cell growth via ERK1/2 mediated mitochondrial dysfunction.

ADAR1 affects HCV infection by modulating innate immune response.

Cytotoxic effects induced by patulin, deoxynivalenol and toxin T2 individually and in combination in hepatic cells (HepG2).

MicroRNA-203 increase cell radiosensitivity via directly targeting Bmi-1 in hepatocellular carcinoma.

Tailoring Platinum(IV) Amphiphiles for Self-Targeting All-in-One Assemblies as Precise Multimodal Theranostic Nanomedicine.

Knockdown of SUMO1P3 represses tumor growth and invasion and enhances radiosensitivity in hepatocellular carcinoma.

Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります